Softwr

Healthcare · head to head

Allscripts vs PathAI

Allscripts logo

Allscripts

Healthcare

Healthcare IT solutions for care coordination

From
On request
Rated
-
Full reviewWebsite
PathAI logo

PathAI

Healthcare

Digital pathology image management with an FDA cleared platform for primary diagnosis

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Allscripts pricing is not publicly available; all quotes require direct contact with sales; PathAI aISight is labelled research use only and cannot be used for primary diagnosis; only AISight Dx carries the FDA clearance and CE-IVD mark, and laboratories regularly buy the wrong configuration and discover they cannot sign out on it.
  • They diverge on capability: Allscripts covers Electronic Health Records, PathAI covers AISight image management.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which Allscripts and PathAI actually diverge.

Attributes where Allscripts and PathAI differ
AttributeAllscriptsPathAI
Founded1986Unknown

Identical on both: starting price (On request), pricing model (quote), free tier (No), platforms (Web), user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Allscripts

  • Electronic Health Records
  • Practice Management
  • Population Health
  • Care Coordination
  • Analytics
  • HL7
  • FHIR
  • Labs

Only in PathAI

  • AISight image management
  • AISight Dx
  • Scanner interoperability
  • Case and worklist management
  • AI algorithm deployment
  • Biopharmaceutical research tooling
  • LIS integration

What people use each for

The jobs each tool is most often brought in to do.

Allscripts

  • Electronic health records and practice management for healthcare providersnot PathAI
  • Healthcare IT solutions for revenue cycle management and patient engagement (now Veradigm)not PathAI

PathAI

  • An academic medical centre going digital for primary diagnosis that needs the FDA cleared AISight Dx configuration rather than the research labelled versionnot Allscripts
  • A reference laboratory consolidating subspecialty sign out across sites so a specialist pathologist can read cases from any locationnot Allscripts
  • A pharmaceutical company needing consistent quantitative scoring of trial biopsies across many sites and readersnot Allscripts
  • A laboratory with a mixed scanner estate that needs one image management layer rather than each scanner vendor viewernot Allscripts

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Allscripts

  • Pricing is not publicly available; all quotes require direct contact with sales
  • Transitioned to Veradigm brand in 2022; legacy Allscripts product line integrated into Veradigm suite

PathAI

  • AISight is labelled research use only and cannot be used for primary diagnosis; only AISight Dx carries the FDA clearance and CE-IVD mark, and laboratories regularly buy the wrong configuration and discover they cannot sign out on it.
  • The software licence is usually the smallest line in a digital pathology project, behind scanners, storage and network capacity, so a business case built around the software cost understates the real investment by a wide margin.
  • Whole slide images are very large, so a laboratory that does not model storage growth and retention policy from the start faces storage costs that grow faster than case volume and dominate the renewal.
  • Clinical validation is required per subspecialty rather than once for the platform, which means dermatopathology, gastrointestinal and breast each need their own concordance study and pathologist time before go live.
  • PathAI competes against pathology incumbents that also sell the scanners, and a laboratory buying an independent image management layer takes on the integration risk between scanner vendor and software vendor itself.

Pricing, plan by plan

Allscripts

On request

No published plan breakdown. See the Allscripts review.

PathAI

On request
  • AISight$undefined/year
    • Priced by annual slide or case volume and by pathologist seats
    • AISight Dx, the clinically cleared configuration, quoted separately from research use AISight
    • Image storage priced by capacity and retention policy

Which should you pick?

Choose Allscripts if

  • You need electronic health records.
  • You also want practice management.
Allscripts review

Choose PathAI if

  • You need aisight image management.
  • You also want aisight dx.
PathAI review

Questions people ask

Is Allscripts or PathAI better?
Neither clearly leads. Allscripts starts at On request and PathAI at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Allscripts or PathAI?
Allscripts starts at On request and PathAI at On request.
Does Allscripts or PathAI run on more platforms?
Both run on Web, so platform support will not decide this one for you.
What is Allscripts best used for?
Allscripts is most often used for electronic health records and practice management for healthcare providers, healthcare it solutions for revenue cycle management and patient engagement (now veradigm). Of those, electronic health records and practice management for healthcare providers and healthcare it solutions for revenue cycle management and patient engagement (now veradigm) are not what PathAI is typically brought in for.
What can Allscripts do that PathAI cannot?
Allscripts covers Electronic Health Records, Practice Management, Population Health, Care Coordination. PathAI covers AISight image management, AISight Dx, Scanner interoperability, Case and worklist management.

Answered from the vendors’ own pages

Allscripts: How do I obtain pricing information for Veradigm solutions?

Veradigm does not publish pricing on their website. Interested buyers must contact a Veradigm Account Executive directly or request a demo to discuss pricing and licensing options tailored to their needs.

Source
PathAI: What is the difference between AISight and AISight Dx?

AISight is for research use only and not for clinical diagnostic use. AISight Dx received FDA 510(k) clearance in June 2025 for primary diagnosis and is CE-IVD marked in the EEA, UK and Switzerland. Only the Dx configuration can be used to sign out cases.

Allscripts: What industries does Veradigm serve?

Veradigm serves four primary market segments: Healthcare Providers, Life Sciences companies, Health Plans and Payers, and Health IT Vendors. Each segment has specialized solutions.

Source
PathAI: Can we use our existing scanners?

Yes. AISight is designed to ingest images from multiple whole slide scanner vendors, which is one of the main reasons laboratories choose an independent image management layer.

Allscripts: Is there a trial available for Veradigm solutions?

Veradigm offers the option to request a demo of their solutions, which is the primary way potential customers can evaluate the platform before making a purchasing decision.

Source
PathAI: Do the AI algorithms carry the same clearance as the platform?

No. The platform clearance covers image management for primary diagnosis. Individual algorithms have their own labelling, and many are research use only. Check each one separately.

PathAI: Is pricing published?

No. It is quoted by slide or case volume, pathologist seats and storage, with the clinically cleared configuration priced separately.

Share

Related pages

More on Allscripts

More on PathAI

Keep looking

Other head to heads